Novartis Dr Ann Aerts, head of the Novartis Foundation, discusses the role the Novartis Foundation plays within low and middle- income countries across the world and how integrating digital health solutions can strengthen health systems and contribute to global health. We at the Novartis Foundation can leverage the expertise of…
Switzerland Lukas Engelberger discusses the challenges and benefits of the healthcare system in Switzerland and the Canton of Basel-Stadt, new milestones in dentistry and the organizational structure between the hospitals and the canton, as well as the federal and cantonal jurisdiction. You are now two years into your four-year mandate as…
Switzerland Carolin Hillebrand, country manager of Neurim Pharmaceuticals Switzerland, a neuroscience specialty company, discusses the launch of their lead product Circadin, the only IP-protected product providing a prolonged release formulation of melatonin for insomnia. Neurim Pharmaceuticals is an Israeli company focused on CNS, with a second office in Switzerland. Could you…
Biomed CEO of Biomed, Dr. Thomas F. Szuran discusses the keys to success for pharma SMEs and the importance of relationship management, investments, and a culture of internal dialogue. Could you start by introducing Biomed to our international readers? We represent companies which are not present in Switzerland directly. Some companies…
Switzerland Walter Steinlin describes the Federal Commission of Technology and Innovation as a catalyst for turning research into innovation. Based in Bern, Switzerland, the commission funds research institutes in corporate projects, and provides mentorship and coaching support for start-ups. Could you give our international audience an overview of the Federal Commission…
Switzerland Jean-Daniel Gerber, chairman of the board at SIFEM, explains why job creation should be the focus of DFIs (Development Finance Institutions) such as SIFEM; how ESG, environmental, social and governance issues, are key to a successful investment, and why we should focus on illnesses that are most prevalent in the…
Biotech Ronald Scott, CEO of Basilea, a biotech company that was spun out of Roche in 2000, talks about launching its first two products, Zevtera and Cresemba; the milestone agreement with the Biomedical Advanced Research and Development Authority (BARDA) to develop Zevtera for the US market; and about the company’s partnering…
Pharma Actelion’s global CEO and co-founder, Dr Jean-Paul Clozel, discusses diversifying the company’s portfolio, prioritizing internal research over inorganic acquisitions, and retaining a spirit of independence and innovation during a period of rapid growth. 2015 was a fantastic year for the company, the best yet, passing the USD two billion…
Pharma André Lüscher of Gilead Switzerland, reveals how the case of Sovaldi demonstrates the challenges for a healthcare system to handle a truly disruptive medical innovation, the knock-on effect on Gilead´s business model, and ensuring that those affected with hepatitis C are able to receive treatment in Switzerland. A lot has…
Generics Andreas Bosshard of Mepha-Teva in Switzerland describes Switzerland’s unique generics market, the quality of the Mepha-Teva brand, innovations within generics, and the company’s growth strategy within the Swiss market. It has been five years since the merger of Teva and Mepha in Switzerland, and curiously the brand name Mepha remains in…
Switzerland Franz Saladin details the unique scope and operations of the Basel Chamber of Commerce, the history of pharmaceuticals in Basel, and the importance of continuously developing the industry within the region and in Switzerland more generally. The Basel Chamber of Commerce is unique in Switzerland due to its broad scope…
Pharma MD Natascha Schill discusses the growing importance and commitment that Biogen has to Switzerland, including a USD one billion investment in new facilities and the creation of 400 jobs in the upcoming years; investing in the local workforce to support the company’s growth. The headline-making news at the moment is…
See our Cookie Privacy Policy Here
